Growth hormone does not flow at a steady drip. The pituitary releases it in pulses, controlled by two opposing pathways. Secretagogue peptides are research tools that tap into those pathways in different ways.
Two Pathways, One Pituitary
The hypothalamus controls growth hormone with two main signals. The first is GHRH, growth hormone releasing hormone, which acts on the GHRH receptor. The second is ghrelin, a hunger hormone that acts on the GHS-R1a receptor.
Both pathways converge on the same somatotroph cells in the pituitary. When researchers stimulate one path, they get a partial release. Stimulating both at once usually produces a larger pulse than either alone. That synergy is why combination studies are common in the literature.
GHRH Analogs: CJC-1295 and Tesamorelin
CJC-1295 is a synthetic GHRH analog. It was modified to resist quick breakdown by enzymes in the blood. Some versions also carry a "DAC" linker that lets them bind to plasma albumin, which extends their half-life from minutes to days.
Tesamorelin is another stabilized GHRH analog. It has been studied in trials related to visceral fat in HIV-associated lipodystrophy and is one of the few GH secretagogues that reached FDA approval for that narrow use. In research settings, both compounds are valued for raising IGF-1 without large spikes in cortisol or prolactin.
Ghrelin Mimetics: Ipamorelin and GHRP-6
Ipamorelin acts on the ghrelin receptor but is unusually selective. In animal work, it triggers GH release without strong effects on appetite, cortisol, or prolactin. That clean profile made it a popular tool compound in pituitary studies.
GHRP-6 is an older ghrelin receptor agonist. It is potent but less selective. Studies report increased hunger, mild cortisol bumps, and prolactin shifts at higher doses. Researchers still use it to probe the ghrelin system, but its broader off-target signal complicates clean readouts.
Combinations and Pulse Behavior
A common research approach is to pair a GHRH analog with a ghrelin mimetic. Hitting both receptors at the same time usually produces a stronger and more natural-looking GH pulse than either compound alone. This pulse-mimicking pattern is one reason these tools are used to study somatotroph physiology.
The strength of the pulse also depends on age, body composition, sleep state, and recent feeding. That is why preclinical studies tightly control timing and baseline conditions. Without those controls, results from different labs can look contradictory.
What Researchers Are Still Working Out
Several questions remain open. How long can repeated stimulation continue before the pituitary becomes desensitized? How do these peptides interact with insulin signaling and glucose handling over time? Are there long-term effects on tumor risk in tissues with active IGF-1 receptors?
Newer studies are also exploring oral and nasal forms, since most secretagogues today require injection. The field is moving toward peptides with cleaner receptor selectivity and longer durations of action. These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption.